(Q28291252)

https://scigraph.springernature.com/pub.10.2165/00023210-200418130-00007

inferred from page(s)

published in

CNS Drugs

0 references

volume

18

0 references

issue

13

0 references

page(s)

933-56

0 references

933-956

0 references

exact match

0 references

cites work

[Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine]

1 reference

12 December 2020

SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome

1 reference

12 December 2020

Lack of effect of amisulpride on the pharmacokinetics and safety of lithium

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers

1 reference

12 December 2020

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

12 December 2020

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

1 reference

12 December 2020

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity

1 reference

12 December 2020

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia

1 reference

12 December 2020

Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

12 December 2020

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

12 December 2020

Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.

1 reference

12 December 2020

Amisulpride is an "atypical" antipsychotic associated with low weight gain

1 reference

12 December 2020

Safety of amisulpride (Solian): a review of 11 clinical studies

1 reference

12 December 2020

Atypical antipsychotics and hyperglycaemia

1 reference

12 December 2020

Switching antipsychotic medications: general recommendations and switching to amisulpride

1 reference

12 December 2020

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

12 December 2020

Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine

1 reference

12 December 2020

Clozapine-associated diabetes

1 reference

12 December 2020

Medico-economic assessment of neuroleptics in schizophrenia. Amisulpride versus haloperidol

1 reference

12 December 2020

Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers

1 reference

12 December 2020

Amisulpride: a review of its use in the management of schizophrenia.

1 reference

12 December 2020

Olanzapine-associated diabetes mellitus

1 reference

12 December 2020

A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

1 reference

12 December 2020

Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality

1 reference

12 December 2020

Hyperprolactinaemia and antipsychotic therapy in schizophrenia

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1 reference

12 December 2020

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

1 reference

12 December 2020

Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects.

1 reference

12 December 2020

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

12 December 2020

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Effects of newer antipsychotics on extrapyramidal function

1 reference

12 December 2020

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.

1 reference

12 December 2020

Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects

1 reference

12 December 2020

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic

1 reference

12 December 2020

From pharmacological profiles to clinical outcomes.

1 reference

12 December 2020

Risperidone-associated diabetes mellitus: a pharmacovigilance study

1 reference

12 December 2020

Amisulpride: from animal pharmacology to therapeutic action

1 reference

12 December 2020

The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers.

1 reference

12 December 2020

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020